Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in drug-resistant focal epilepsy
NCT03283371Phase 2Completed
- Sponsor
- Biogen
- Start
- Mar 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in focal epilepsy, sponsored by Biogen. Started Mar 2018; status: completed.
02
Drugs
natalizumab
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT03283371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283371.